Artal Group S.A. Neurocrine Biosciences Inc Put Options Transaction History
Artal Group S.A.
- $1.58 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
622Shares Held
95.2MCall Options Held
661KPut Options Held
221K-
Black Rock Inc. New York, NY14.2MShares$1.65 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.17 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$535 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$287 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$274 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.1B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...